1. Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer. (3rd July 2019) Authors: Tucker, Matthew D.; Zhu, Jason; Marin, Daniele; Gupta, Rajan T.; Gupta, Santosh; Berry, William R.; Ramalingam, Sundhar; Zhang, Tian; Harrison, Michael; Wu, Yuan; Healy, Patrick; Lisi, Stacey; George, Daniel J.; Armstrong, Andrew J. Journal: Cancer medicine Issue: Volume 8:Number 10(2019:Aug.) Page Start: 4644 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Issue 28 (1st October 2021) Authors: Rose, Tracy L.; Harrison, Michael R.; Deal, Allison M.; Ramalingam, Sundhar; Whang, Young E.; Brower, Blaine; Dunn, Mary; Osterman, Chelsea K.; Heiling, Hillary M.; Bjurlin, Marc A.; Smith, Angela B.; Nielsen, Matthew E.; Tan, Hung-Jui; Wallen, Eric; Woods, Michael E.; George, Daniel; Zhang, Tian... Journal: Journal of clinical oncology Issue: Volume 39:Issue 28(2021) Page Start: 3140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment‐related neuroendocrine prostate cancer resulting in Cushing's syndrome. (21st October 2016) Authors: Ramalingam, Sundhar; Eisenberg, Adva; Foo, Wen Chi; Freedman, Jennifer; Armstrong, Andrew J; Moss, Larry G; Harrison, Michael R Journal: International journal of urology Issue: Volume 23:Number 12(2016) Page Start: 1038 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗